Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model
- PMID: 19902227
- DOI: 10.1007/s00384-009-0819-7
Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model
Abstract
Purpose: Surgical cytoreduction of peritoneal surface malignancy of colorectal origin in combination with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) has become an established treatment approach. Only a few of animal models for scientific research on various therapeutic strategies have been described yet. The feasibility of an established rat model with a peritoneal surface malignancy from colorectal origin for treatment investigation should be examined in this study.
Methods: Peritoneal surface malignancy of colonic origin was induced in 90 male BD IX rats. Animals were randomised into six groups (15 animals per one control and five treatment groups). One treatment group underwent only surgical debulking. The animals of the other four treatment groups received additional interventions: hyperthermic intraperitoneal chemotherapy with mitomycin or gemcitabine, photodynamic therapy or taurolidine lavage. Twenty-one days after treatment, the intraperitoneal status was investigated. Tumour weight, count of tumour nodules and experimental Peritoneal Carcinosis Index (ePCI) were detected.
Results: Extended surgical cytoreduction and additional treatments including HIPEC were feasible in this rat model. All treatment groups had a significant lower tumour weight, account of tumour nodes and ePCI if compared with the control group. Comparing the additional therapies only HIPEC with mitomycin lead to relevant tumour reduction after surgery.
Conclusion: This rat model is suitable for research on the multimodal treatment of peritoneal malignancies. A persisting cytoreductive effect of surgical tumour debulking could be proven. Only additional HIPEC therapy with mitomycin showed a significant tumour reduction. This animal model provides the opportunity to investigate different therapeutic strategies.
Similar articles
-
First surgical tumour reduction of peritoneal surface malignancy in a rat's model.Clin Exp Metastasis. 2008;25(4):445-9. doi: 10.1007/s10585-008-9150-x. Epub 2008 Feb 27. Clin Exp Metastasis. 2008. PMID: 18301991
-
Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.BMC Cancer. 2006 Jun 22;6:162. doi: 10.1186/1471-2407-6-162. BMC Cancer. 2006. PMID: 16792796 Free PMC article.
-
A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis.BMC Cancer. 2005 May 30;5:56. doi: 10.1186/1471-2407-5-56. BMC Cancer. 2005. PMID: 15924622 Free PMC article.
-
Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.Clin Colorectal Cancer. 2012 Sep;11(3):167-76. doi: 10.1016/j.clcc.2012.01.001. Epub 2012 Mar 6. Clin Colorectal Cancer. 2012. PMID: 22397952 Review.
-
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.Asian J Surg. 2021 Jan;44(1):221-228. doi: 10.1016/j.asjsur.2020.05.010. Epub 2020 Jun 27. Asian J Surg. 2021. PMID: 32605790 Review.
Cited by
-
Effect of Intraperitoneal Chemotherapy with Regorafenib on IL-6 and TNF-α Levels and Peritoneal Cytology: Experimental Study in Rats with Colorectal Peritoneal Carcinomatosis.J Clin Med. 2023 Nov 23;12(23):7267. doi: 10.3390/jcm12237267. J Clin Med. 2023. PMID: 38068319 Free PMC article.
-
Investigation of the effectiveness of hyperthermic intraperitoneal chemotherapy in experimental colorectal peritoneal metastasis model.Pleura Peritoneum. 2023 May 10;8(3):123-131. doi: 10.1515/pp-2023-0002. eCollection 2023 Sep. Pleura Peritoneum. 2023. PMID: 37662606 Free PMC article.
-
Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo.BMC Cancer. 2017 Mar 24;17(1):216. doi: 10.1186/s12885-017-3204-x. BMC Cancer. 2017. PMID: 28340556 Free PMC article.
-
Advances in the management of peritoneal malignancies.Nat Rev Clin Oncol. 2022 Nov;19(11):698-718. doi: 10.1038/s41571-022-00675-5. Epub 2022 Sep 7. Nat Rev Clin Oncol. 2022. PMID: 36071285 Review.
-
Establishment of an Experimental System for Intraperitoneal Chemotherapy in a Rat Model.In Vivo. 2021 Sep-Oct;35(5):2703-2710. doi: 10.21873/invivo.12554. In Vivo. 2021. PMID: 34410959 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical